New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 31, 2014
12:39 EDTBAX, HALOFDA panel says HyQvia has favorable benefit-risk ratio, Bloomberg reports
The panel voted 15-1 that the drug from Baxter (BAX) and Halozyme (HALO) has a favorable risk/benefit in treatment of primary immune deficiency disorders, according to Bloomberg.
News For BAX;HALO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 18, 2014
07:37 EDTBAXStifel to hold a conference
Subscribe for More Information
November 12, 2014
08:02 EDTBAXCredit Suisse to hold a conference
Subscribe for More Information
07:27 EDTBAXNorth American Spine Society to hold annual meeting
Subscribe for More Information
November 11, 2014
09:18 EDTHALOHalozyme price target lowered to $10 from $12 at JMP Securities
JMP Securities cut its price target on Halozyme after the company said it intends to explore partnerships and/or strategic alternatives for the Hylenex program in diabetes. The firm removed the diabetes program from its valuation due to uncertainty. It reiterates an Outperform rating on the shares.
November 10, 2014
18:32 EDTHALOOn The Fly: After Hours Movers
Subscribe for More Information
17:26 EDTHALOHalozyme completes workforce reduction
The company noted, "We completed a corporate reorganization to align with strategic priorities. This reorganization resulted in a workforce reduction of 22 employees. We will incur a one-time charge in Q414 that will be largely offset by reduced compensation expenses during the quarter."
16:19 EDTHALOHalozyme reports Q3 EPS (16c), consensus (14c)
Subscribe for More Information
15:54 EDTBAXAmerican Society of Nephrology to hold a conference
Subscribe for More Information
15:26 EDTHALONotable companies reporting after market close
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use